Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. A grant from National Institutes of Health, worth up to $1.5M.

Amount: up to $1.5M
Type: Grant

Key facts

Key facts for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Amount	up to $1.5M
Issuer	National Institutes of Health
Who can apply	Small businesses, companies, universities and 7 more
Sectors	HealthTech
Deadline	Closes 05 Nov 2027

Unlock application details

See all eligibility criteria, required documents and the official application link. Free account, no card.

Update history

Source: grants.gov ↗

Source checked 2 days ago

85 days agoagentImported from the official source

Opportunities with the same funding type or region
European Degree Exploratory Action		Closes 18 Feb 2027
Cooperative Agreement for affiliated Partner with Alaska Cooperative Ecosystem Studies Unit	up to $234,460	Closes 07 Dec 2026
Cooperative Agreement for affiliated Partner with Colorado Plateau Cooperative Ecosystem Studies Unit	up to $150,000	Closes 07 Dec 2026